Monitor for any future disclosures regarding changes in executive compensation or strategic direction that may result from the expanded role. No trading action warranted based on this filing alone.
VIR drugs
VIR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $9.10entry
- T+1 · 9mo ago +4.95%α +6.26% · $9.55
- T+5 · 8mo ago +4.18%α +6.41% · $9.48
- T+20 · 8mo ago −0.44%α +3.35% · $9.06
- T+60 · 6mo ago −0.77%α −12.07% · $9.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an internal leadership expansion with no immediate financial impact or executive departure.
Key Facts
- Marianne De Backer, current CEO and principal executive officer, was appointed to the additional role of President on March 4, 2026
- No executive departures were reported
- No compensation details were disclosed in the filing
- The appointment reflects a consolidation of leadership roles under the existing CEO
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Potential concentration of power in a single executive without checks and balances
- Lack of disclosed succession planning if De Backer holds both CEO and President roles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-091447 |
| Document: 0001193125-26-091447-index-headers.html | 0001193125-26-091447 |
| Document: 0001193125-26-091447-index.html | 0001193125-26-091447 |
| Document: 0001193125-26-091447.txt | 0001193125-26-091447 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers